CVS HEALTH CORPORATION CVS

CVS Health Corporation, junto con sus subsidiarias, es una empresa de servicios de salud. La compañía opera a través de cuatro segmentos: Servicios de Farmacia, Retail/LTC, Beneficios de Atención Médica y Corporativo/Otros. El segmento de Servicios de Farmacia ofrece una variedad de soluciones de gestión de beneficios de farmacia (PBM), incluyendo ofertas de diseño de planes y administración, servicios de gestión de redes de farmacias minoristas, farmacia por correo, farmacia especializada, servicios clínicos, servicios de gestión de enfermedades y gestión de gastos médicos. El segmento de Retail/LTC vende medicamentos con receta y una variedad de productos de salud y bienestar y mercancía general. Su segmento de Beneficios de Atención Médica ofrece una variedad de productos tradicionales, voluntarios y de seguros de salud dirigidos al consumidor y servicios relacionados. Tiene aproximadamente 9,900 ubicaciones minoristas, más de 1,100 clínicas médicas sin cita previa, un administrador de beneficios de farmacia con aproximadamente 105 millones de miembros del plan, servicios de farmacia especializada y un negocio de atención farmacéutica para personas mayores.

Con 11 acciones de CVS (USD 957,83) habrías recibido USD 29,48 en dividendos en los últimos 12 meses.

CVS hizo una división de acciones (split) de 2:1 el 7 de junio de 2005: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 5 oct

  Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

  Zacks highlights two medical stocks with positive Earnings Surprise Prediction (ESP): CVS Health and Solventum. Both stocks have positive ESP figures and are expected to report earnings in early November 2026, suggesting potential for earnings beats based on recent analyst revisions.

  

• Zacks Investment Research 30 sept

  DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace?

  Danaher Corporation's Biotechnology segment drove growth with 4% reported sales increase to $1.92 billion in Q2 2026, bolstered by strong China demand and consumables sales. Despite regional headwinds in Western Europe and North America, DHR expects mid-single-digit core growth in 2026. The stock trades at a premium valuation of 24.92X forward P/E versus the industry average of 16.59X and carries a Zacks Rank #3 (Hold).

  

• Zacks Investment Research 21 sept

  CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors

  CVS Health stock declined 1.4% to $87.60, underperforming the broader market which gained 1.49%. The stock has fallen 4.49% over the past month. The company is expected to report flat EPS of $1.6 for the upcoming quarter with revenue projected at $105.04 billion (up 2.11% YoY). CVS holds a Zacks Rank #3 (Hold) rating and trades at a Forward P/E of 11.07, below its industry average of 17.31.

  

• Zacks Investment Research 17 sept

  BTSG Faces $200M IRA Hit but Efficiency May Protect Profitability

  BrightSpring Health Services' Home and Community Pharmacy segment experienced an 8% revenue decline to $540M in Q2, with the Inflation Reduction Act (IRA) accounting for approximately $50M of the impact. Despite a projected $200M revenue headwind in 2026 from IRA pricing changes, the company expects only a $15M EBITDA impact, demonstrating that operational efficiency gains from technology, automation, AI, and Lean initiatives are offsetting regulatory pressures. Peer companies Cardinal Health and CVS Health are similarly navigating IRA-driven revenue pressures while maintaining profitability through service agreements and operational improvements.

  

• Zacks Investment Research 16 sept

  Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure?

  Cardinal Health expects fiscal 2027 IRA pricing changes to create similar revenue headwinds as 2026, but management aims to preserve compensation and maintain profitability through distribution agreements and operational efficiency. Peers BrightSpring and CVS Health also face IRA-related revenue pressure but are offsetting impacts through operational improvements and specialty pharmacy growth.